CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for LadRx Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

LadRx Corp
11726 San Vicente Blvd., Suite 650
Phone: (310) 826-5648p:310 826-5648 LOS ANGELES, CA  90049  United States Ticker: LADXLADX
Business Summary
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board, Independent Director Jennifer K.Simpson 54 7/27/2022 7/29/2021
Chief Executive Officer StephenSnowdy 54 1/10/2022 1/10/2022
Chief Financial Officer, Senior Vice President, Treasurer John Y.Caloz 71 1/1/2022 10/26/2007
Independent Director Joel K.Caldwell 68 1/1/2020 7/12/2017
Independent Director Cary J.Claiborne 62 8/9/2022 8/9/2022

Subsidiaries
Business Name Address City State/Province Country
INNOVIVE Pharmaceuticals, Inc. 555 Madison Avenue New York NY United States

Business Names
Business Name
Centurion BioPharma Corporation
CYTR
Innovive Pharmaceuticals, Inc.
LADX
LADXD

General Information
Number of Employees: 2 (As of 12/31/2023)
Outstanding Shares: 495,092 (As of 12/31/2023)
Shareholders: 180
Stock Exchange: OTC
Federal Tax Id: 581642740
Fax Number: (310) 826-6139
Email Address: webmaster@cytrx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024